NUVB News and Press, Nuvation Bio Inc. Class A From 02/20/26

2026-02-20 13:14:21 ET Overview My last evaluation of Nuvation Bio ( NUVB ) was in August 2025. While I acknowledged IBTROZI’s appeal in ROS1+ NSCLC, relative to other TKIs like AUGTYRO and ROZLYTREK, I also noted that it’s a small market and competition—in ...

Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026 PR Newswire NEW YORK , Feb. 17, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challeng...

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Feb. 17, 2026 /CNW/ -- Equity-Insider.com   News Commentary – More than 2,100 oncology clinical trials...

Protocol amendment to change SIGMA from a Phase 2 to a Phase 3 study now complete The currently enrolling SIGMA trial will now include patients with grade 2 astrocytoma with high-risk features in the maintenance setting, in addition to previously eligible patients with high-grade astrocyt...

2026-02-02 00:48:40 ET Introduction Nuvation Bio ( NUVB ) is an early commercial-stage biotech company, led by prominent research scientist Dr. David Hung. Its lead asset, IBTROZI, a targeted therapy for ROS1-positive non-small cell lung cancer (NSCLC), was approved by the F...

2026-01-13 22:16:00 ET Nuvation Bio Inc. (NUVB) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 6:45 PM EST... Read the full article on Seeking Alpha For further details see: Nuvation Bio Inc. (NUVB) Presents at 44th Annual J.P. Morgan Healthcare Conference Tr...

2026-01-12 13:39:27 ET More on the markets Powell Under Attack The Bullish Trend Everyone Is Waiting For, But Nobody's Looking At DOJ Vs. Powell: We Have A Valuation Problem (And 2 Strategies For Now) Wall Street pushes higher despite Powell investigation ...

2026-01-12 09:05:22 ET from H.C. Wainwright issued a price target of $17.00 for NUVB on 2026-01-12 13:51:07. The adjusted price target was set to $17.00. At the time of the announcement, NUVB was trading at $6.52. The overall price target consensus is at $12.25 with high...

2026-01-12 08:41:27 ET More on Nuvation Bio Nuvation Bio: A Strong Company Now Fairly Priced Nuvation Bio to discontinue development of NUV-1511 Nuvation Bio rises as B. Riley starts at Buy on launch trajectory for lead drug Read the full article on Seeking...

Successfully started 216 patients on IBTROZI ® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025 Preliminary IBTROZI net product revenue of approximately $15.7 million in the fourth quarter and $2...